Use of Atosiban in in Vitro Fertilization (IVF) Treatment

PHASE4CompletedINTERVENTIONAL
Enrollment

800

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

December 31, 2013

Study Completion Date

December 31, 2013

Conditions
Subfertility
Interventions
DRUG

Atosiban

Patients in the atosiban group will receive intravenous atosiban 30 min before the transfer with a bolus dose of 6.75 mg, and the infusion will be continued with an infusion rate of 18 mg/h. After performing ET, the dose of atosiban will be reduced to 6 mg/h and the infusion will be continued for 2 hours (total administered dose: 37.5 mg). Those in the placebo group will receive normal saline only.

DRUG

Normal saline

Normal saline given

Trial Locations (2)

510515

Reproductive Medical Center of Nanfang Hospital, Guangzhou

Unknown

CGRH, School of Medicine, Ho Chi Minh City

All Listed Sponsors
collaborator

Vietnam National University

OTHER

collaborator

Nanfang Hospital, Southern Medical University

OTHER

lead

The University of Hong Kong

OTHER

NCT01501214 - Use of Atosiban in in Vitro Fertilization (IVF) Treatment | Biotech Hunter | Biotech Hunter